Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rhTSH Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone

NCT00137891
View directory record Official record
Conditions
Healthy
Interventions
Modified Release rhTSH
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 6, 2026, 2:20 AM EDT
Recruiting Phase 2 Interventional

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

NCT05668962
View directory record Official record
Conditions
Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer
Interventions
Selpercatinib, Sodium Iodine I-131, rhTSH
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Early Phase 1 Interventional

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

NCT02145143
View directory record Official record
Conditions
Thyroid Carcinoma
Interventions
Vemurafenib, serial 124I PET/CT, thyrotropin alpha
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 6, 2026, 2:20 AM EDT
Active, not recruiting No phase listed Observational

CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer

NCT04495985
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 6, 2026, 2:20 AM EDT
Terminated Phase 2 Interventional Results available

Research Examining Gulf War Illness in Our Nations Service Members

NCT01846182
View directory record Official record
Conditions
Gulf War Illness
Interventions
Duloxetine, Pregabalin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
44 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Temple, Texas • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 6, 2026, 2:20 AM EDT
Recruiting Phase 2 Interventional

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

NCT03841617
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Thyrogen, I-131, I-124, Thyroid hormone withdrawal
Drug · Radiation · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 6, 2026, 2:20 AM EDT
Terminated Phase 4 Interventional Results available

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

NCT00328926
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Phase 4 Interventional

Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.

NCT00001730
View directory record Official record
Conditions
Hypothyroidism, Thyroid Neoplasms
Interventions
Thyrogen
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 2:20 AM EDT
Terminated Not applicable Interventional

Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)

NCT00926978
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Radioactive Iodine 124
Radiation
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Phase 1 Interventional

Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123

NCT02278198
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
rhTSH
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Not applicable Interventional Results available

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

NCT00970359
View directory record Official record
Conditions
Thyroid Cancer
Interventions
AZD6244
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 6, 2026, 2:20 AM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer

NCT00525135
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Valproic Acid
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

NCT00085293
View directory record Official record
Conditions
Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
Interventions
Decitabine, Iodine I 131, Recombinant thyrotropin alfa, Fludeoxyglucose F 18, Positron emission tomography
Drug · Radiation · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
Aurora, Colorado • Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

NCT00071838
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 6, 2026, 2:20 AM EDT
Recruiting Phase 1 Interventional

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

NCT03647358
View directory record Official record
Conditions
Thyroid Carcinoma, Metastatic Thyroid Carcinoma
Interventions
PET/CT Scan, Iodine-124
Device · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 6, 2026, 2:20 AM EDT
Terminated Not applicable Interventional Results available

Trial of Verapamil in Chronic Rhinosinusitis

NCT02454608
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
Verapamil HCl, Placebo
Drug · Other
Lead sponsor
Benjamin Bleier
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Phase 2 Interventional Results available

Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer

NCT00181168
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Euthyroid Group
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 6, 2026, 2:20 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

NCT04873869
View directory record Official record
Conditions
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Interventions
NBI-921352, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
2 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids

NCT05128383
View directory record Official record
Conditions
Keloid
Interventions
Dupilumab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Phase 3 Interventional

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

NCT00295763
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Thyrogen (thyrotropin alfa for injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Phase 2 Interventional

Zenapax to Treat Multiple Sclerosis

NCT00001934
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Zenapax
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Sep 6, 2026, 2:20 AM EDT
Recruiting Phase 2 Interventional

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

NCT06440850
View directory record Official record
Conditions
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Biospecimen Collection, Cobimetinib, Computed Tomography, Diagnostic Imaging, I-131 Uptake Test, Iodine I-131, Magnetic Resonance Imaging, Positron Emission Tomography, Recombinant Thyrotropin Alfa, Ultrasound Imaging, Vemurafenib
Procedure · Drug · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 6, 2026, 2:20 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF

NCT01687712
View directory record Official record
Conditions
Infertility
Interventions
AFOLIA, Gonal-f® RFF
Drug
Lead sponsor
Fertility Biotech AG
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Tempe, Arizona • Encino, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 6, 2026, 2:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression

NCT01412918
View directory record Official record
Conditions
Tinnitus
Interventions
The Inhibitor™ Tinnitus Masking Device
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 6, 2026, 2:20 AM EDT